They are developing a prospective, randomized, comparative study to evaluate the efficacy of anticancer chemotherapy in predicting prognosis and determining chemotherapy method in early Hormone Receptor-positive breast cancer patients.
| Contact Details | 15F G-HIGHCITY, 243 Digital-ro, Guro-gu, Seoul, Korea TEL: +82-2-2621-7038 |
|---|
Find out more companies
Related products
-
DiagnosticsTASCOM (YidoBio)
TASCOM (YidoBio)’s R&D Center focuses on developing cell therapy for the treatment of diabetes with leading scientists working with key doctors in the field. TASCOM (YidoBio) also distributes diabetic and related medical supplies from top manufacturers such as BD, Arkray, and i-SENS.
-
-
-
-
